Live
Clinical OMICsCAR T-Cell Therapy Expands Access to Kidney TransplantsEndpoints NewsAlnylam to pay $30M upfront to AI startup Inceptive in RNA R&D dealFierceBiotechLilly, Boehringer to slash at least $1B each from planned investments in GermanyClinical OMICsGenetically Raised Pulse Pressure Predisposes to Dementia-Linked DeathClinical OMICsEngineered Islets Could Eliminate Need for Immunosuppression in Type 1 DiabetesFierceBiotechUnlocking Unstructured Data with AI for Optimized Protocol DevelopmentEndpoints NewsBristol Myers turns focus to AI costs after broad rollout to workersClinical OMICsNew Tumor Survival Mechanism Revealed in Aggressive ALT CancersClinical OMICsVeracyte Launches Test Identifying Breast Cancer Patients Who Don’t Need ChemoEndpoints NewsAxsome pushes back generic entry for narcolepsy drug until 2040Clinical OMICsNanotube Sensor Provides Chemical Imaging for Earlier Detection of Bladder Cancer RecurrenceEndpoints NewsFDA guides pharma on explaining unapproved drugs to payors
Endpoints News Mar 2, 2026

FDA lifts hold on second Intellia Phase 3 gene editing trial

FDA lifts hold on second Intellia Phase 3 gene editing trial

Original
Body unavailable. Use the original source.